98%
921
2 minutes
20
Background The recurrence of hypersensitivity reaction (HSR) to low-osmolar iodinated contrast media (LOCM) remains challenging despite premedication and substitution of the LOCM. Purpose To determine the optimal practical preventive strategy for LOCM substitution in patients with a history of prior immediate HSR to LOCM. Materials and Methods In a retrospective study, patients with an immediate HSR to LOCM before February 2020 and who underwent subsequent exposure to LOCM until March 2021 were enrolled in five tertiary referral hospitals in South Korea. The association of recurrence of an HSR after subsequent LOCM exposures was assessed using multivariate general estimating equation analysis according to age, sex, the severity of the index HSR, premedication, and substituting LOCM based on common carbamoyl side chains, including the -(2,3-dihydroxypropyl)-carbamoyl and -(2,3-dihydroxypropyl)--methyl-carbamoyl moieties. Results The evaluation included 3800 subsequent LOCM exposures in 1066 patients (mean age, 56.2 years ± 13.5 [SD]; 567 [53%] female and 499 [47%] male patients). The general estimating equation analysis, using 1:1 propensity score matched data for age, sex, HSR severity, and LOCM selection, showed that premedication with corticosteroids significantly reduced recurrent HSR (odds ratio [OR], 0.72; 95% CI: 0.52, 1.00; = .049). The change to another LOCM with a common side chain had a similar recurrence rate as using the same LOCM (OR, 0.98; 95% CI: 0.64, 1.50; = .93), whereas the use of a different LOCM without a common side chain significantly lowered HSR recurrence (OR, 0.51; 95% CI: 0.37, 0.69; < .001) in multivariate general estimating equation analysis. Substitution of an LOCM without a common side chain was effective regardless of the index HSR severity but was more pronounced in moderate-to-severe reactions (OR, 0.30; 95% CI: 0.16, 0.55; < .001). Conclusion For patients with a previous immediate HSR of any severity to LOCM, alternative LOCM without a common carbamoyl side chain reduced recurrent HSR during subsequent exposures. © RSNA, 2023 See also the editorial by McDonald in this issue.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1148/radiol.222467 | DOI Listing |
Cureus
July 2025
Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, JPN.
Objective To compare the effects of two low-osmolar contrast media (LOCM), iohexol and iomeprol, on renal function in patients undergoing percutaneous coronary intervention (PCI), as measured by estimated glomerular filtration rate (eGFR). Methods This retrospective study included 180 patients who underwent PCI between January 2021 and December 2022. After propensity score matching based on age, sex, diabetes mellitus, pre-PCI eGFR, contrast media volume, and left ventricular ejection fraction, 88 patients who received either iohexol or iomeprol (44 each) were analyzed.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
August 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Drug Safety Center, Seoul National University Hospital, Seoul, Korea; Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, Korea; Department of Internal Medicine, Seo
Background: With the increasing use of low-osmolar contrast media (LOCM), hypersensitivity reactions (HSRs) to LOCM have become more common. Although guidelines for the preventive measure for immediate reactions are well established, evidence-based strategies for nonimmediate HSRs remain limited.
Objective: To determine effective prophylactic strategies for patients with nonimmediate HSRs to LOCM.
Eur Radiol
October 2025
Global Medical Affairs, GE Healthcare, Braunschweig, Germany.
Objectives: This systematic review and meta-analysis aimed to assess and compare acute adverse reactions (AAR) rates among non-ionic low-osmolar contrast media (LOCM), examining administration routes and severity-specific impact on AAR rates.
Materials And Methods: A PubMed and Cochrane Library search identified studies published between January 1989 and March 2024. Inclusion criteria focused on studies with > 100 adult patients who received intra-arterial or intravenous LOCM (iobitridol, iohexol, iomeprol, iopamidol, iopromide, and ioversol).
J Invasive Cardiol
September 2025
Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota. Email:
Objectives: The impact of contrast type in chronic total occlusion (CTO) percutaneous coronary intervention (PCI) remains controversial. The authors sought to evaluate the impact of contrast medium selection on patients undergoing CTO PCI.
Methods: The authors examined the outcomes of patients who underwent CTO PCI using iso-osmolar (iodixanol) vs pooled low-osmolar contrast media (LOCM) using data from the PROGRESS-CTO registry.
J Med Imaging Radiat Sci
January 2025
Department of Radiation Oncology, Temerty Faculty of Medicine, The University of Toronto, Canada. Electronic address:
Background: Computed tomography (CT) has revolutionized medical imaging, enabling cross-sectional evaluation of the human body. The increasing utilization of iodinated contrast media (ICM) in contrast-enhanced CT scans has raised concerns about potential adverse reactions. This literature review investigates the efficacy of premedication regimens in preventing severe allergic reactions to intravenous ICM.
View Article and Find Full Text PDF